Application of the apparent diffusion coefficient in magnetic resonance imaging in an assessment of the early response to treatment in Hodgkin’s and non-Hodgkin’s lymphoma – pilot study
More details
Hide details
Publication date: 2018-05-12
Pol J Radiol, 2018; 83: 210-214
Lymphoproliferative neoplasms are the largest and most frequently diagnosed entities in the group of haema­tological malignancies. The aim of the study was to assess whether apparent diffusion coefficient (ADC) measured on the first day of the second cycle of chemotherapy could be a predictor of prognosis and of the final treatment’s outcome.

Material and methods:
The study included 27 patients with diagnosed Hodgkin’s and non-Hodgkin’s lymphoma, who had magnetic resonance (MR) performed with diffusion weighted imaging/apparent diffusion coefficient (DWI/ADC) before and on the first day of the second cycle of chemotherapy. Imaging was performed using a 1.5 T MR scanner. ADC was measured in lymphoma infiltration in the area of the lowest signal in the ADC map and the highest signal on β 800 images in post-treatment study. After that, the corresponding area was determined in a pre-treatment study and an ADC value was measured.

The difference between ADC values in pre-treatment (ADC = 720 mm2/s) and post-treatment (ADC = 1059 mm2/s) studies was statistically significant (p < 0.001). Cutoff values for estimating response to treatment were established at the level of ADC 1080 mm2/s, and ADC to muscle ratio at 0.82 in post-treatment study. Patients with ADC > 752 mm2/s before treatment manifested lower probability of progression than patients with ADC < 752 mm2/s.

ADC measurement’s before treatment and on the first day of the second cycle of chemotherapy can be used as a prognostic marker in lymphoma therapy. ADC values lower than 1080 mm2/s and an increase of the ratio after the treatment can be considered as a marker of disease progression.

Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. J Clin Oncol 2014; 32: 3059-3067.
Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond : evolving concepts and practical applications The 2008 WHO classification of lymphoid neoplasms and beyond : evolving concepts and practical applications. 2014; 117: 5019-5033.
Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007; 25: 571-578.
Asenbaum U, Nolz R, Karanikas G, et al. Evaluation of [18F]-FDG-based hybrid imaging combinations for assessment of bone marrow involvement in lymphoma at initial staging. PLoS One 2016; 11: 1-12.
Albano D, Patti C, La Grutta L, et al. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Eur J Radiol 2016; 85: 313-318.
Azzedine B, Kahina MB, Dimitri P, et al. Whole-body diffusion- weighted MRI for staging lymphoma at 3.0T: Comparative study with MR imaging at 1.5T. Clin Imaging 2015; 39: 104-109.
Lin C, Itti E, Luciani A, et al. Whole-body diffusion-weighted imaging in lymphoma. Cancer Imaging 2010; 10: 172-178.
Johnson SA, Kumar A, Matasar MJ, et al. Imaging for Staging and Response Assessment in Lymphoma. Radiology 2015; 276: 323-338.
Wu X, Pertovaara H, Korkola P, et al. Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma. PLoS One 2014; 9: 1-8.
Kwee TC, Takahara T, Ochiai R, et al. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): Features and potential applications in oncology. Eur Radiol 2008; 18: 1937-1952.
Kwee TC, Basu S, Torigian DA, et al. Evolving importance of diffusion-weighted magnetic resonance imaging in lymphoma. PET Clin 2012; 7: 73-82.
Padhani AR, Koh DM, Collins DJ. Whole-Body Diffusion-weighted MR Imaging in Cancer: Current Status and Research Directions. Radiology 2011; 261: 700-718.
Chen Y, Zhong J, Wu H, et al. The clinical application of whole-body diffusion-weighted imaging in the early assessment of chemotherapeutic effects in lymphoma: The initial experience. Magn Reson Imaging 2012; 30: 165-170.
Stéphane V, Samuel B, Vincent D, et al. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. Eur J Radiol 2013; 82: 2011-2017.
Frampas E. Lymphomas: Basic points that radiologists should know. Diagn Interv Imaging 2013; 94: 131-144.
Mosavi F, Wassberg C, Selling J, et al. Whole-body diffusion-weighted MRI and 18F-FDG PET/CT can discriminate between different lymphoma subtypes. Clin Radiol 2015; 70: 1229-1236.
Usuda K, Maeda S, Motono N, et al. Diffusion weighted imaging can distinguish benign from malignant mediastinal tumors and mass lesions: Comparison with positron emission tomography. Asian Pacific J Cancer Prev 2015; 16: 6469-6475.
Journals System - logo
Scroll to top